Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Open-label Study of MT-6548 in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan

Next Previous
Trial Profile

A Phase III, Open-label Study of MT-6548 in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 23 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vadadustat (Primary)
  • Indications Anaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Mitsubishi Tanabe Pharma Corporation

    • Most Recent Events

    • 23 Jul 2019 According to Akebia Therapeutics Media Release, the company announced that Mitsubishi Tanabe Pharma Corporation has submitted a Japanese New Drug Application (JNDA) to the Ministry of Health, Labor and Welfare in Japan for manufacturing and marketing approval of vadadustat as a treatment for anemia due to chronic kidney disease (CKD) based on two pivotal studies and two additional Phase 3 single-arm studies.
    • 18 Mar 2019 According to Mitsubishi Tanabe Pharma Corporation Media Release, based on data from these two pivotal studies as well as from two additional single-arm studies in peritoneal dialysis and hemodialysis subjects the company expects to submit a Japanese New Drug Application in 2019.
    • 12 Mar 2019 According to an Akebia Therapeutics Media Release, the company will discuss these findings on investor update call. Additional data from the studies are expected be presented by Mitsubishi Tanabe Pharma Corporation at an upcoming medical meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top